MX2009004461A - Formas de dosificacion del clorhidrato de palonosetron que tienen estabilidad y biodisponibilidad mejorada. - Google Patents
Formas de dosificacion del clorhidrato de palonosetron que tienen estabilidad y biodisponibilidad mejorada.Info
- Publication number
- MX2009004461A MX2009004461A MX2009004461A MX2009004461A MX2009004461A MX 2009004461 A MX2009004461 A MX 2009004461A MX 2009004461 A MX2009004461 A MX 2009004461A MX 2009004461 A MX2009004461 A MX 2009004461A MX 2009004461 A MX2009004461 A MX 2009004461A
- Authority
- MX
- Mexico
- Prior art keywords
- bioavailability
- improved stability
- palonosetron hydrochloride
- soft capsules
- dosage forms
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4816—Wall or shell material
- A61K9/4825—Proteins, e.g. gelatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5052—Proteins, e.g. albumin
- A61K9/5057—Gelatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
Landscapes
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Hospice & Palliative Care (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Otolaryngology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Siempre que sean formas de dosificación orales sólidas del clorhidrato de palonosetron, los métodos para usar las formas de dosificación para tratar el vómito, y los métodos para hacer los formas de dosificación. Los formas de dosificación han mejorado la estabilidad y biodisponibilidad, y están preferiblemente bajo la forma de cápsulas rellenas de líquido.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US85434206P | 2006-10-24 | 2006-10-24 | |
PCT/EP2007/009098 WO2008049552A1 (en) | 2006-10-24 | 2007-10-19 | Soft capsules comprising palonosetron hydrochloride having improved stability and bioavailability |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2009004461A true MX2009004461A (es) | 2009-09-16 |
Family
ID=38921772
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2009004461A MX2009004461A (es) | 2006-10-24 | 2007-10-19 | Formas de dosificacion del clorhidrato de palonosetron que tienen estabilidad y biodisponibilidad mejorada. |
Country Status (36)
Country | Link |
---|---|
US (2) | US20080152704A1 (es) |
EP (1) | EP1940366B9 (es) |
JP (1) | JP5144527B2 (es) |
KR (1) | KR101441459B1 (es) |
CN (1) | CN101573106B (es) |
AR (1) | AR063362A1 (es) |
AT (1) | ATE427742T1 (es) |
AU (1) | AU2007308378B2 (es) |
BR (1) | BRPI0718497B1 (es) |
CA (1) | CA2666512C (es) |
CL (1) | CL2007003055A1 (es) |
CO (1) | CO6160289A2 (es) |
CR (1) | CR10728A (es) |
CY (1) | CY1109914T1 (es) |
DE (1) | DE602007000856D1 (es) |
DK (1) | DK1940366T3 (es) |
EA (1) | EA016455B1 (es) |
ES (1) | ES2325339T3 (es) |
GT (1) | GT200900096A (es) |
HK (1) | HK1117769A1 (es) |
HN (1) | HN2009000785A (es) |
HR (1) | HRP20090341T1 (es) |
IL (1) | IL198225A (es) |
ME (1) | ME01949B (es) |
MX (1) | MX2009004461A (es) |
NO (1) | NO342353B1 (es) |
NZ (1) | NZ576237A (es) |
PL (1) | PL1940366T3 (es) |
PT (1) | PT1940366E (es) |
RS (1) | RS50842B (es) |
SI (1) | SI1940366T1 (es) |
SV (1) | SV2009003238A (es) |
TW (1) | TWI367212B (es) |
UA (1) | UA97653C2 (es) |
WO (1) | WO2008049552A1 (es) |
ZA (1) | ZA200902773B (es) |
Families Citing this family (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ZA200806496B (en) * | 2006-01-27 | 2009-12-30 | Eurand Inc | Drug delivery systems comprising weakly basic drugs and organic acids |
NZ570039A (en) * | 2006-01-27 | 2011-07-29 | Eurand Inc | Drug delivery systems comprising weakly basic selective serotonin 5-HT3 blocking agent and organic acids |
WO2010077669A2 (en) | 2008-12-08 | 2010-07-08 | Teva Pharmaceutical Industries Ltd. | Palonosetron formulation |
US20110003005A1 (en) * | 2009-07-06 | 2011-01-06 | Gopi Venkatesh | Methods of Treating PDNV and PONV with Extended Release Ondansetron Compositions |
CN102048705B (zh) * | 2009-11-10 | 2012-07-18 | 齐鲁制药有限公司 | 盐酸帕洛诺司琼口腔崩解片制剂及其制备方法 |
EP2499137A1 (en) * | 2009-11-13 | 2012-09-19 | Helsinn Healthcare S.A. | Palonosetron metabolites |
ES2494015T3 (es) * | 2009-11-18 | 2014-09-12 | Helsinn Healthcare Sa | Composiciones para tratar nauseas y vómitos de origen central |
EP2722045B1 (en) | 2009-11-18 | 2016-07-06 | Helsinn Healthcare SA | Compositions for treating centrally mediated nausea and vomiting |
PL2744497T3 (pl) | 2011-10-18 | 2016-10-31 | Terapeutyczne połączenia netupitantu i palonosetronu | |
CN107137374B (zh) * | 2012-06-02 | 2020-04-07 | 正大天晴药业集团股份有限公司 | 帕洛诺司琼的固体药物组合物 |
US20160287524A1 (en) * | 2013-03-19 | 2016-10-06 | Galenicum Health S.L. | Pharmaceutical compositions comprising an active agent |
US10195153B2 (en) | 2013-08-12 | 2019-02-05 | Pharmaceutical Manufacturing Research Services, Inc. | Extruded immediate release abuse deterrent pill |
US9492444B2 (en) | 2013-12-17 | 2016-11-15 | Pharmaceutical Manufacturing Research Services, Inc. | Extruded extended release abuse deterrent pill |
WO2015095391A1 (en) | 2013-12-17 | 2015-06-25 | Pharmaceutical Manufacturing Research Services, Inc. | Extruded extended release abuse deterrent pill |
WO2015099381A1 (ko) * | 2013-12-23 | 2015-07-02 | 주식회사 삼양바이오팜 | 팔로노세트론을 함유하는 약학 조성물 |
CA2955229C (en) | 2014-07-17 | 2020-03-10 | Pharmaceutical Manufacturing Research Services, Inc. | Immediate release abuse deterrent liquid fill dosage form |
EP3209282A4 (en) | 2014-10-20 | 2018-05-23 | Pharmaceutical Manufacturing Research Services, Inc. | Extended release abuse deterrent liquid fill dosage form |
KR20160128573A (ko) * | 2015-04-29 | 2016-11-08 | 주식회사 삼양바이오팜 | 약제학적 패키지 |
JP2019019067A (ja) * | 2017-07-13 | 2019-02-07 | ニプロ株式会社 | 液体製剤 |
CN111205283A (zh) * | 2020-01-20 | 2020-05-29 | 广州九植医药科技有限公司 | 一种盐酸帕洛诺司琼有关物质b的合成方法 |
EP4385500A1 (en) | 2022-12-12 | 2024-06-19 | Alfred E. Tiefenbacher (GmbH & Co. KG) | Fixed dose combination comprising netupitant and palonosetron |
EP4385497A1 (en) | 2022-12-12 | 2024-06-19 | Alfred E. Tiefenbacher (GmbH & Co. KG) | Antioxidant-free fixed dose combination of netupitant and palonosetron |
Family Cites Families (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB1015251A (en) * | 1963-03-12 | 1965-12-31 | Glaxo Lab Ltd | Aqueous pharmaceutical compositions in capsule form |
US4182914A (en) * | 1974-01-22 | 1980-01-08 | Nippon Oil Company Limited | Process for continuously producing diisopropyl ether |
US4695578A (en) * | 1984-01-25 | 1987-09-22 | Glaxo Group Limited | 1,2,3,9-tetrahydro-3-imidazol-1-ylmethyl-4H-carbazol-4-ones, composition containing them, and method of using them to treat neuronal 5HT function disturbances |
US4937247A (en) * | 1985-04-27 | 1990-06-26 | Beecham Group P.L.C. | 1-acyl indazoles |
EP0200444B1 (en) * | 1985-04-27 | 1992-11-11 | Beecham Group Plc | Azabicyclononyl-indazole-carboxamide having 5-ht antagonist activity |
GB8516083D0 (en) * | 1985-06-25 | 1985-07-31 | Glaxo Group Ltd | Heterocyclic compounds |
US5578628A (en) * | 1985-06-25 | 1996-11-26 | Glaxo Group Limited | Medicaments for the treatment of nausea and vomiting |
US5240954A (en) * | 1985-06-25 | 1993-08-31 | Glaxo Group Limited | Medicaments |
US4906755A (en) * | 1986-11-03 | 1990-03-06 | Merrell Dow Pharmaceuticals Inc. | Esters of hexahydro-8-hydroxy-2,6-methano-2H-quinolizin-3-(4H)-one and related compounds |
US5011846A (en) * | 1988-02-23 | 1991-04-30 | Merrell Dow Pharmaceuticals Inc. | Medicament compositions derived from quinolizine and quinolizinone and methods of use thereof |
US5344658A (en) * | 1989-06-28 | 1994-09-06 | Glaxo Group Limited | Process and composition using ondansetron |
GB8914804D0 (en) * | 1989-06-28 | 1989-08-16 | Glaxo Group Ltd | Process |
IE68434B1 (en) * | 1989-11-28 | 1996-06-12 | Syntex Inc | New tricyclic compounds |
GB9405304D0 (en) * | 1994-03-16 | 1994-04-27 | Scherer Ltd R P | Delivery systems for hydrophobic drugs |
GB9423511D0 (en) * | 1994-11-22 | 1995-01-11 | Glaxo Wellcome Inc | Compositions |
US20030095926A1 (en) * | 1997-10-01 | 2003-05-22 | Dugger Harry A. | Buccal, polar and non-polar spray or capsule containing drugs for treating disorders of the gastrointestinal tract or urinary tract |
US20040136914A1 (en) * | 1997-10-01 | 2004-07-15 | Dugger Harry A. | Buccal, polar and non-polar spray containing ondansetron |
US6294548B1 (en) * | 1998-05-04 | 2001-09-25 | Hoffmann-La Roche Inc. | Multidose vial formulations for administering endo-N-(9-methyl-9-azabicyclo[3.3.1]non-3-yl)-1-methyl-1H-indazole-3-carboxamide hydrochloride |
FR2818905A1 (fr) * | 2000-12-28 | 2002-07-05 | Cll Pharma | Compositions pharmaceutiques colloidales micellaires renfermant un principe actif lipophile |
FR2823118B1 (fr) * | 2001-04-04 | 2004-03-19 | Lavipharm Lab Inc | Nouvelle composition filmogene a usage topique et son utilisation pour la delivrance d'agents actifs |
FR2827770B1 (fr) * | 2001-07-27 | 2005-08-19 | Gattefosse Ets Sa | Composition pharmaceutique a usage oral comprenant un principe actif susceptible de subir un important effet de premier passage intestinal |
WO2004045615A1 (en) * | 2002-11-15 | 2004-06-03 | Helsinn Healthcare Sa | Palonosetron for the treatment of chemotherapy-induced emesis |
TWI355936B (en) * | 2003-02-18 | 2012-01-11 | Helsinn Healthcare Sa | Uses of palonosetron hydrochloride |
IL159729A0 (en) | 2004-01-06 | 2004-06-20 | Doron I Friedman | Non-aqueous composition for oral delivery of insoluble bioactive agents |
-
2007
- 2007-10-19 NZ NZ576237A patent/NZ576237A/en unknown
- 2007-10-19 RS RSP-2009/0222A patent/RS50842B/sr unknown
- 2007-10-19 PL PL07819163T patent/PL1940366T3/pl unknown
- 2007-10-19 DE DE602007000856T patent/DE602007000856D1/de active Active
- 2007-10-19 EP EP07819163A patent/EP1940366B9/en active Active
- 2007-10-19 ME MEP-2009-222A patent/ME01949B/me unknown
- 2007-10-19 TW TW096139121A patent/TWI367212B/zh active
- 2007-10-19 ES ES07819163T patent/ES2325339T3/es active Active
- 2007-10-19 SI SI200730033T patent/SI1940366T1/sl unknown
- 2007-10-19 KR KR1020097010252A patent/KR101441459B1/ko active IP Right Grant
- 2007-10-19 DK DK07819163T patent/DK1940366T3/da active
- 2007-10-19 CN CN2007800395678A patent/CN101573106B/zh active Active
- 2007-10-19 CA CA2666512A patent/CA2666512C/en active Active
- 2007-10-19 MX MX2009004461A patent/MX2009004461A/es active IP Right Grant
- 2007-10-19 AT AT07819163T patent/ATE427742T1/de active
- 2007-10-19 BR BRPI0718497-2A patent/BRPI0718497B1/pt active IP Right Grant
- 2007-10-19 WO PCT/EP2007/009098 patent/WO2008049552A1/en active Application Filing
- 2007-10-19 PT PT07819163T patent/PT1940366E/pt unknown
- 2007-10-19 JP JP2008540633A patent/JP5144527B2/ja active Active
- 2007-10-19 UA UAA200905038A patent/UA97653C2/ru unknown
- 2007-10-19 AU AU2007308378A patent/AU2007308378B2/en active Active
- 2007-10-19 EA EA200970396A patent/EA016455B1/ru unknown
- 2007-10-24 US US11/877,722 patent/US20080152704A1/en not_active Abandoned
- 2007-10-24 CL CL200703055A patent/CL2007003055A1/es unknown
- 2007-10-24 AR ARP070104694A patent/AR063362A1/es unknown
-
2008
- 2008-11-11 HK HK08112341.3A patent/HK1117769A1/xx unknown
-
2009
- 2009-04-17 CR CR10728A patent/CR10728A/es unknown
- 2009-04-19 IL IL198225A patent/IL198225A/en active IP Right Grant
- 2009-04-21 ZA ZA200902773A patent/ZA200902773B/xx unknown
- 2009-04-23 GT GT200900096A patent/GT200900096A/es unknown
- 2009-04-23 HN HN2009000785A patent/HN2009000785A/es unknown
- 2009-04-24 SV SV2009003238A patent/SV2009003238A/es unknown
- 2009-04-24 CO CO09041709A patent/CO6160289A2/es unknown
- 2009-05-19 NO NO20091945A patent/NO342353B1/no unknown
- 2009-06-12 HR HR20090341T patent/HRP20090341T1/xx unknown
- 2009-07-03 CY CY20091100702T patent/CY1109914T1/el unknown
-
2016
- 2016-10-20 US US15/298,630 patent/US20170035748A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
UA97653C2 (ru) | Мягкие капсулы, содержащие палоносетрона гидрохлорид, которые имеют улучшенную стабильность и биологическую доступность | |
IL208832A (en) | 3-Aminocarbazole Compound, Pharmaceutical Preparations Containing Them, Methods of Preparation and Use for Drug Preparation | |
EP2120878A4 (en) | DOSAGE FORM WITH TWO OR MORE PHARMACEUTICAL ACTIVITIES IN DIFFERENT PHYSICAL FORMS | |
HK1220631A1 (zh) | 用於遞送治療劑的陰離子核心組合物以及製備和使用所述組合物的方法 | |
LT2046298T (lt) | Farmacinė vaisto forma, turinti farmaciniu požiūriu priimtiną soliubilizuojančią kompoziciją | |
EP1972251A4 (en) | CAPSULE TYPE CONTAINER AND ADMINISTRATION METHOD USING THE SAME | |
ZA200705750B (en) | Compositions and methods for stabilizing active pharmaceutical ingredients | |
EP1804832A4 (en) | METHOD AND COMPOSITIONS FOR THE NADLESS DELIVERY OF MACROMOLECULES | |
UA106636C2 (uk) | Морфолінотіазоли як позитивні алостеричні модулятори альфа 7 | |
HK1123789A1 (en) | Azabicyclic derivatives, preparation method thereof and pharmaceutical compositions containing same | |
IL212880A0 (en) | Sufentanil solid dosage forms comprising oxygen scavengers and methods of using the same | |
WO2009031606A1 (ja) | 関節炎治療及び予防剤 | |
WO2008030818A3 (en) | Novel liposome compositions | |
HK1142823A1 (en) | Formulations for the oral administration of therapeutic agents and related methods | |
WO2005076829A3 (en) | Stable loratadine spill resistant formulation | |
SG10201408374WA (en) | Therapeutic Combinations Of Theobromine And An Antihistamine | |
ZA200701443B (en) | Pharmaceutical composition in the form of a gastric-resident tablet containing an active principle | |
EA201190282A1 (ru) | Фармацевтическая композиция, содержащая тамсулозин | |
TW200800977A (en) | A new salt | |
GB2443377A (en) | Anti-malarial composition comprising artesunate and lumefantrine | |
MX2009008813A (es) | Composicion farmaceutica que contiene floroglucinol y paracetamol. | |
WO2011161223A3 (en) | Pharmaceutical oral dosage forms comprising lercanidipine and enalapril and their pharmaceutically acceptable salts | |
EP1994003A4 (en) | PIPERIDINE DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF, THEIR USE AS THERAPEUTIC AGENTS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEY | |
TW200833375A (en) | Pharmaceutical compositions | |
PL1877035T3 (pl) | Kompozycja farmaceutyczna i postać galenowa szybko rozpadająca się w jamie ustnej oraz sposób jej wytwarzania |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Grant or registration |